ClinicalTrials.gg
CompletedNCT00701090Updated Mar 10, 2017Results posted

A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)

A Phase 3 interventional study of sitagliptin and Comparator: glimepiride in Type 2 Diabetes Mellitus, Non Insulin Dependent and Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,035
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
11th of 197
1,035 · median 102
Started
2008
with 22 others
Phase 3
74 of 198
none open now
Registered
46th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 46th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride. This study will also see if this treatment is safe and tolerable.

03

Conditions studied

  • Type 2 Diabetes Mellitus, Non Insulin Dependent
  • Diabetes Mellitus, Non-Insulin-Dependent

Keywords

  • Type 2 Diabetes Mellitus
  • Non Insulin Dependent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Diagnosed with type 2 diabetes
  • On a stable dose of metformin of at least 1500 mg per day

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes
  • Pregnant
  • positive
  • On a weight loss program or medication
  • Has a history of blood disorder, certain cancers, heart, liver or kidney disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,035 participants (actual)

Study arms

  • Experimental
    1

    sitagliptin

    Drug: sitagliptin · Drug: open-label metformin

  • Active comparator
    2

    glimepiride

    Drug: Comparator: glimepiride · Drug: open-label metformin

Interventions

  • Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks

    Also known as: Januvia

  • DrugGlimepirideStudies of GlimepirideGlimepiride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.

    Also known as: metformin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at Week 30

    Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Week 0 to Week 30

Secondary outcomes

  1. Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30

    Change from baseline at Week 30 was defined as Week 30 minus Week 0.

    Time frame: Week 0 to Week 30

  2. Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30

    Time frame: Week 0 to Week 30

  3. Change From Baseline in Body Weight at Week 30

    Change from baseline at Week 30 was defined as Week 30 minus Week 0.

    Time frame: Week 0 to Week 30

  4. Percent of Patients With A1C <7.0% at Week 30

    Time frame: Week 30

  5. Percent of Patients With A1C <6.5% at Week 30

    Time frame: Week 30

07

Results

Posted Oct 5, 2010

Participant flow

Phase III First Patient In: 14-May-2008; Last Patient Last Visit: 27-Oct-2009; 109 study centers worldwide

Participant flow — Overall Study
MilestoneSitagliptinGlimepiride
Started516519
Completed468468
Not completed4851
Withdrew: Adverse event112
Withdrew: Death01
Withdrew: Lack of efficacy54
Withdrew: Lost to follow-up99
Withdrew: Physician decision34
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject1116
Withdrew: Other712

Outcome measures

PrimaryChange From Baseline in HbA1c at Week 30

Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Week 0 to Week 30
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c at Week 30
PercentSitagliptinGlimepiride
Change From Baseline in HbA1c at Week 30-0.47 (-0.55 to -0.39)-0.54 (-0.62 to -0.45)
Statistical analysis
  • Sitagliptin vs Glimepiride · Mean difference (net): 0.07 · 95% CI -0.03 to 0.16ANCOVA model with terms: treatment, country, and baseline HbA1c.
SecondaryChange From Baseline in FPG (Fasting Plasma Glucose) at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0.

Time frame:
Week 0 to Week 30
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30
mg/dLSitagliptinGlimepiride
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30-14.6 (-17.9 to -11.2)-17.5 (-20.8 to -14.1)
Statistical analysis
  • Sitagliptin vs Glimepiride · Mean difference (net): 2.9 · 95% CI -0.9 to 6.7ANCOVA model terms: treatment, country, and baseline.
SecondaryPercent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30
Time frame:
Week 0 to Week 30
Reported as:
Number · Percentage of Participants
Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30
Percentage of ParticipantsSitagliptinGlimepiride
Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 307.022.0
Statistical analysis
  • Sitagliptin vs Glimepiride · Miettinen &Nurminen method · p = <0.001 · Risk difference (rd): -15.0 · 95% CI -19.3 to -10.9Miettinen \&Nurminen method was used for the 95% confidence interval
SecondaryChange From Baseline in Body Weight at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0.

Time frame:
Week 0 to Week 30
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 30
KilogramsSitagliptinGlimepiride
Change From Baseline in Body Weight at Week 30-0.8 (-1.1 to -0.5)1.2 (0.9 to 1.5)
Statistical analysis
  • Sitagliptin vs Glimepiride · ANCOVA · p = <0.001 · Mean difference (net): -2.0 · 95% CI -2.3 to -1.6ANCOVA model terms: treatment, country, and baseline.
SecondaryPercent of Patients With A1C <7.0% at Week 30
Time frame:
Week 30
Reported as:
Number · Percentage of Participants
Percent of Patients With A1C <7.0% at Week 30
Percentage of ParticipantsSitagliptinGlimepiride
Percent of Patients With A1C <7.0% at Week 3052.459.6
Statistical analysis
  • Sitagliptin vs Glimepiride · Odds ratio (or): 0.65 · 95% CI 0.47 to 0.90The parameter estimate and 95% CI represent the odds of having A1C \<7.0% at Week 30 in the Sitagliptin group vs. the Glimepiride group, computed using a logistic regression model controlling for treatment, country and baseline A1C.
SecondaryPercent of Patients With A1C <6.5% at Week 30
Time frame:
Week 30
Reported as:
Number · Percentage of Participants
Percent of Patients With A1C <6.5% at Week 30
Percentage of ParticipantsSitagliptinGlimepiride
Percent of Patients With A1C <6.5% at Week 3021.227.5
Statistical analysis
  • Sitagliptin vs Glimepiride · Odds ratio (or): 0.67 · 95% CI 0.47 to 0.95The parameter estimate and 95% CI represent the odds of having A1C \<6.5% at Week 30 in the Sitagliptin group vs. the Glimepiride group, computed using a logistic regression model controlling for treatment, country and baseline A1C.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—16/516 (3.1%)58/519 (11.2%)
Glimepiride—11/518 (2.1%)134/518 (25.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventSitagliptinGlimepiride
Myocardial ischaemiaCardiac disorders2/5160/518
ThrombocytopeniaBlood and lymphatic system disorders1/5160/518
Inguinal herniaGastrointestinal disorders1/5160/518
MastitisInfections and infestations1/5160/518
Peritonsillar abscessInfections and infestations1/5160/518
Typhoid feverInfections and infestations1/5160/518
Humerus fractureInjury, poisoning and procedural complications1/5160/518
Patella fractureInjury, poisoning and procedural complications1/5160/518
Skin lacerationInjury, poisoning and procedural complications1/5160/518
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/5160/518
Most frequent other events
Most frequent other events
EventSitagliptinGlimepiride
HypoglycaemiaMetabolism and nutrition disorders36/519114/518
NasopharyngitisInfections and infestations25/51936/518

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinGlimepirideTotal
Mean56.3 ± 9.756.2 ± 10.156.3 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinGlimepirideTotal
Female232240472
Male284279563
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SitagliptinGlimepirideTotal
White297298595
Black6612
Asian109111220
American Indian/Alaska Native252651
Other7978157
A1C (Hemoglobin A1c)
A1C (Hemoglobin A1c)(Percent)SitagliptinGlimepirideTotal
Mean7.50 ± 0.707.51 ± 0.767.50 ± 0.73
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011 Feb;13(2):160-8. doi: 10.1111/j.1463-1326.2010.01334.x. PubMed 21199268 ↗
  • Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Ther. 2015 Mar;6(1):29-40. doi: 10.1007/s13300-015-0098-y. Epub 2015 Jan 30. Erratum In: Diabetes Ther. 2015 Mar;6(1):97-8. doi: 10.1007/s13300-015-0101-7. PubMed 25633134 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2008
First posted
Jun 19, 2008
Start
May 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Oct 5, 2010
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00701090
Responsible party
Sponsor
First posted
Jun 19, 2008
Start date
May 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Oct 5, 2010
Last update
Mar 10, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion